-
2026-10-10
GenSci's Oncology Innovation: NDA Approval Secured for Prostate CancerLearn More
-
2026-10-09
GenSci's Two Innovations Received IND Clearance from NMPALearn More
-
2026-09-03
GenSci Showcases Innovation at CPHI Korea 2026Learn More
-
2026-08-13
GenSci's Ophthalmology Pipeline: IND Approval Secured for Three IndicationsLearn More
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2026-05-15
GenSciP166 Selected as Late-Breaking Abstract at SID 2026Learn More
-
2026-05-07
GenSci's Firsekibart Injection Receives Approval by NMPALearn More
-
2026-04-29
GenSci’s NK3R Antagonist for VMS Phase II Study Results Published in MenopauseLearn More
-
2026-04-27
GenSci Presents Multiple Innovative Oncology Pipelines at AACR 2026Learn More
-
2026-03-17
Positive Phase II Results for GenSci's Firsekibart in Pediatric Rare Disease PublishedLearn More
-
2026-03-11
GenSci128, an Investigational Cancer Therapy from Gensci Pharmaceuticals, Receives FDA Orphan Drug Designation for Pancreatic CancerLearn More